Yalda Mostofi Bravo

This inventor holds 20 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignees: Tempest Therapeutics, Inc., Inception 2, Inc., Novira Therapeutics, Inc.. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yalda Mostofi Bravo. Retrieved from https://idiyas.com/inventor/yalda-mostofi-bravo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 8)

% Patents Active = 75.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 9)

Average Co-Inventor Count = 5.9

ph-index = 3

Forward Citations = 27(Granted Patents)

Company Filing History:

10 out of 10

Tempest Therapeutics, Inc.

Novira Therapeutics, Inc.

patents

4. 2 out of 3

Contineum Therapeutics, Inc.

patents

5. 2 out of 4

Pipeline Therapeutics, Inc.

patents

Years Active: 2016-2026

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12565501 - Muscarinic acetylcholine Mreceptor antagonists (2026-03-03),

2. 12390462 - Muscarinic acetylcholine M1 receptor antagonists (2025-08-19),

3. 12215093 - Bicyclic carboxamides and methods of use thereof (2025-02-04),

4. 11795156 - Bicyclic carboxamides and methods of use thereof (2023-10-24),

5. 11752149 - Muscarinic acetylcholine M1 receptor antagonists (2023-09-12),

6. 11738009 - Bicyclic compounds and their use in the treatment of cancer (2023-08-29),

7. 11666557 - Triazolone compounds and uses thereof (2023-06-06),

8. 11638704 - Bicyclic compounds and their use in the treatment of cancer (2023-05-02),

9. 11512090 - Muscarinic acetylcholine Mreceptor antagonists (2022-11-29),

10. 11472789 - Bicyclic carboxamides and methods of use thereof (2022-10-18),

11. 11066405 - Bicyclic compounds and their use in the treatment of cancer (2021-07-20),

12. 10968201 - Bicyclic carboxamides and methods of use thereof (2021-04-06),

13. 10710959 - Sulfide alkyl compounds for HBV treatment (2020-07-14),

14. 10568871 - Triazolone compounds and uses thereof (2020-02-25),

15. 10196351 - Sulfide alkyl compounds for HBV treatment (2019-02-05),

Title: The Innovations of Yalda Mostofi Bravo

Introduction: Yalda Mostofi Bravo, an innovative inventor based in San Diego, CA, has made significant contributions to the field of pharmaceutical sciences. With an impressive portfolio of 18 patents, her work primarily focuses on the modulation of receptor activities that have implications for treating various diseases.

Latest Patents: Among her most recent patents are essential advancements in bicyclic carboxamides, which provide compounds, compositions, and methods for modulating the activity of EP and EP receptors. These inventions offer potential treatments, prevention, and amelioration of one or more symptoms associated with diseases linked to EP and EP receptor activities. Certain embodiments of these compounds serve as antagonists of both EP and EP receptors, showcasing her dedication to the development of innovative therapeutic solutions.

Career Highlights: Yalda Mostofi Bravo's career is marked by her collaboration with notable companies in the biotechnology sector, including Tempest Therapeutics, Inc. and Novira Therapeutics, Inc. Her efforts have contributed to advancing drug discovery and the development of effective treatment methodologies.

Collaborations: Throughout her career, Yalda has worked alongside talented colleagues, including Austin Chih-Yu Chen and Nicholas Simon Stock. These collaborations exemplify the collective expertise that drives innovation in her field.

Conclusion: Yalda Mostofi Bravo is not only an accomplished inventor but also a pivotal figure in the pharmacological landscape. Her groundbreaking patents and collaborative spirit continue to influence the treatment of diseases through innovative approaches, solidifying her position as an influential contributor to her field.

Profile summary based on public USPTO records.